Nanomix

About Nanomix

Nanomix, headquartered in Emeryville, California, is a leader in the development of mobile and affordable point-of-care diagnostic solutions. The company focuses on providing rapid and accurate diagnostic information through its handheld testing platform and assays. These solutions are designed to be used in settings where timely diagnosis is crucial for clinical decision-making and improved patient care. Nanomix's flagship product, the S1 Assay, detects and quantifies three key markers in blood to aid in the rapid detection of serious infections such as sepsis and bacteremia. The S1 Assay has received CE Mark approval and is currently under review by the U.S. FDA. Additionally, the company has developed rapid point-of-care tests for COVID-19, which have been recognized for their potential to support safe reopening during the pandemic. Nanomix serves healthcare providers who require immediate diagnostic results to make informed decisions, particularly in emergency and critical care settings. The company operates in the medical diagnostics market and follows a business model that includes the sale of diagnostic devices and assays. Revenue is generated through the direct sale of these products to healthcare facilities and through partnerships and contracts, such as the one awarded by BARDA for the development of COVID-19 tests. Keywords: point-of-care diagnostics, mobile testing, rapid detection, sepsis, COVID-19, handheld device, clinical decision-making, affordable healthcare, S1 Assay, BARDA contract.